Immix Biopharma, Inc. IMMX Deferred Tax Assets Amortization Of Capitalized Research And Development
Deferred Tax Assets Amortization Of Capitalized Research And Development at other companies
Other financials
Where this comes from
Reported directly by Immix Biopharma, Inc. in its filing.
Tagged under the XBRL concept IMMX:DeferredTaxAssetsAmortizationOfCapitalizedResearchAndDevelopment.
The official record: Immix Biopharma, Inc.’s 10-K/A, filed March 27, 2026, on SEC EDGAR. View the filing →
Ask your AI about Immix Biopharma, Inc.'s deferred tax assets amortization of capitalized research and development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Immix Biopharma, Inc.'s deferred tax assets amortization of capitalized research and development?
- Immix Biopharma, Inc. (IMMX) reported deferred tax assets amortization of capitalized research and development of $3.03M in Q4 2025.
- What is the long-term trend for Immix Biopharma, Inc.'s deferred tax assets amortization of capitalized research and development?
- Over 3 years (2022 to 2025), Immix Biopharma, Inc.'s deferred tax assets amortization of capitalized research and development has grown at a 43.8% compound annual growth rate (CAGR), from $1.02M to $3.03M.
- What does deferred tax assets amortization of capitalized research and development mean?
- This metric captures the deferred tax benefit arising from the difference between the tax treatment and financial reporting of capitalized research and development costs. It reflects the timing differences in when R&D expenses are recognized for tax purposes versus accounting purposes. This asset indicates future tax savings potential as these capitalized costs are amortized over time.